Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Tau Imaging with an [18F]MK-6240 Tracer

Start: March 1, 2021
End: June 2024
Enrollment: 200

What Is This Study About?

This study will evaluate use of the tau tracer [18F]MK-6240 to image the brains of individuals from families with a known autosomal dominant Alzheimer's disease mutation. Participants will undergo positron emission tomography (PET) imaging of the brain to measure the level of tau, a protein found in a harmful form in the brain of people with Alzheimer's disease. 

Do I Qualify To Participate in This Study?

Minimum Age: 18 Years

Maximum Age: N/A

Must have:

  • Eligible to enroll in the Dominantly Inherited Alzheimer Network (DIAN) and DIAN Extended Registry (DIAN EXR) studies
  • Cognitively normal or with mild dementia
  • Able and willing to undergo MRI, CT or PET radioactive tracer injection; those unable to undergo MRI will have CT
  • Premenopausal women will undergo a pregnancy test within 24 hours of drug administration

Must NOT have:

  • Any condition that could increase risk to the participant, limit the participant's ability to tolerate the experimental procedures, or interfere with the collection/analysis of the data
  • Unable to perform the imaging procedures for any reason (e.g., electronic medical devices, inability to lie still for long periods)
  • Hypersensitivity to [18F]MK-6240 or any of its excipients
  • Women who are currently pregnant or breastfeeding; women who do not agree to use reliable contraception or to refrain from sexual activity for 24 hours following the [18F]MK-6240 injection
  • Currently participating in any research study receiving an active study medication for Alzheimer's, an investigational drug, device, imaging, or placebo within the past 30 days
  • Other than the DIAN study, current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed allowable limits

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Study Contact
Jasmin Chua, MS
Alyssa Gonzales

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Missouri
Washington University School of Medicine
Saint Louis, MO 63110
Recruiting
Jasmin Chua, MS

Who Sponsors This Study?

Lead: Washington University School of Medicine

Source: ClinicalTrials.gov ID: NCT04104659

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health